Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central nervous procedure, conolidine modulates alternate molecular targets. A Science Innovations review identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://paulu973zeb5.humor-blog.com/profile